Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial

  1. Trang chủ
  2. Quốc tế
  3. USA
  4. Austin
  5. Doanh nghiệp (B2B)
  6. Doanh nghiệp Bán
  1. Posted by: [email protected]
  2. Member since: June 2026
  3. Posted:
  4. Danh muc: Doanh nghiệp Bán
  5. Khu vực: Austin (Astin)
  6. Đăng bài ID: 63684214
Genentech’s Phase III Krascendo 1 trial shows divarasib significantly improves progression-free survival over approved KRAS G12C inhibitors in advanced NSCLC patients.

Austin, Businesses For Sale, Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial
Trở lại Tiếp theo
Gửi Email cho bạn bè

Ask AI to Review This Ad

Vấn đề với quảng cáo này?


How to Avoid Scams